Sandra Zurawski
38Patents
10h-index
29Co-inventors
75Inventor score
Filing activity: Sep 4, 1986 → Jun 6, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5696234A | Muteins of mammalian cytokine interleukin-13 | Human Necessities | 42 | Expired |
| US9102734B2 | Fusion proteins comprising antibody and HPV E6 and E7 antigens | Emerging Cross-Sectional Technologies | 39 | Active |
| US8449888B2 | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells | Chemistry; Metallurgy | 34 | Active |
| US8236934B2 | Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR) | Chemistry; Metallurgy | 32 | Active |
| US8728481B2 | Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR) | Chemistry; Metallurgy | 30 | Active |
| US8057798B2 | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells | Chemistry; Metallurgy | 28 | Active |
| US9102730B2 | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells | Chemistry; Metallurgy | 25 | Active |
| US8586052B2 | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells | Chemistry; Metallurgy | 25 | Active |
| US9234040B2 | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells | Chemistry; Metallurgy | 25 | Active |
| US9109011B2 | Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef | Chemistry; Metallurgy | 13 | Active |
| US6479638B1 | Antibodies that specifically bind DNAX leukocyte associated immunoglobulin-like receptor | Chemistry; Metallurgy | 10 | Expired |
| US5017692A | Truncated human interleukin-a alpha | Chemistry; Metallurgy | 10 | Expired |
| US8481314B2 | Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1) | Emerging Cross-Sectional Technologies | 9 | Active |
| US9339556B2 | Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1) | Emerging Cross-Sectional Technologies | 9 | Active |
| US9562104B2 | Anti-CD40 antibodies | Emerging Cross-Sectional Technologies | 5 | Active |
| US9315580B2 | Vaccines directed to langerhans cells | Chemistry; Metallurgy | 5 | Active |
| US6676939B2 | Methods of modulating IL-174 response | Emerging Cross-Sectional Technologies | 2 | Expired |
| US10286058B2 | Vaccines against HPV and HPV-related diseases | Chemistry; Metallurgy | 2 | Active |
| US7999078B2 | Antibodies that bind DNAX leukocyte associated immunoglobulin-like receptor | Emerging Cross-Sectional Technologies | 2 | Active |
| US9567401B2 | Anti-CD40 antibodies | Emerging Cross-Sectional Technologies | 1 | Active |
| US5136022A | T cell activation markers | Chemistry; Metallurgy | 1 | Expired |
| US10683361B2 | Anti-CD40 antibodies | Emerging Cross-Sectional Technologies | 1 | Active |
| US10087256B2 | Method of making an anti-CD40 antibody | Emerging Cross-Sectional Technologies | 1 | Active |
| US10610585B2 | Methods and compositions for treating and preventing HIV | Chemistry; Metallurgy | 0 | Active |
| US12214034B2 | Vaccines against HPV and HPV-related diseases | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.